TABLE 1.
Drug class | Drug(s) tested | Susceptibility test resulta | Resistance gene(s) |
---|---|---|---|
Aminoglycosides | NDb | ND | armA, aac(3)-IV, aac(6')-Ib-cr, aadA1, aadA16, aadA2, aph(3'')-Ib, aph(3')-Ia, aph(4)-Ia, aph(6)-Id |
Monobactams | Aztreonam | S | None identified |
Carbapenems | Meropenem | S | None identified |
β-Lactams (cephalosporins) | Ceftriaxone | S | blaDHA-1, blaSHV-28 |
Cefepime | S | ||
Cefuroxime | R | ||
Cefixime | R | ||
Penicillins | Piperacillin | R | |
Ampicillin-sulbactam | R | ||
Fluoroquinolones | Levofloxacin | R | oqxA, oqxB, qnrB2, qnrB4 |
Moxifloxacin | R | ||
Tetracyclines | Tetracycline | I | None identified |
Tigecycline | I | ||
Minocycline | S | ||
Phenicols | Chloramphenicol | R | cmlA1, floR |
Rifampin | ND | ND | ARR-3 |
Trimethoprim | Trimethoprim | R | dfrA27 |
Fosfomycin | ND | ND | fosA, mdf(A) |
Macrolides | ND | ND | mph(E), msrE |
Sulfonamides | ND | ND | sul1, sul3 |
Polymyxins | Colistin | S (I/R)c | mcr-8 |
Resistance classifications are based on CLSI guidelines (16) and the Vitek 2 Advanced Expert System. S, susceptible; R, resistant; I, intermediate.
ND, not done.
The isolate tested intermediate on the Vitek 2 system and the Etest and resistant on the MicroScan system using the 2020 CLSI breakpoints (17).